Publications by authors named "L Iaccarino"
Introduction: Alzheimer's disease is partially characterized by the progressive accumulation of aggregated tau-containing neurofibrillary tangles. Although the association between accumulated tau, neurodegeneration, and cognitive decline is critical for disease understanding and clinical trial design, we still lack robust tools to predict individualized trajectories of tau accumulation. Our objective was to assess whether brain imaging biomarkers of flortaucipir-positron emission tomography (PET), in combination with clinical and genomic measures, could predict future pathological tau accumulation.
View Article and Find Full Text PDFArticle Synopsis
- HE4 is a protein that helps promote fibrosis by preventing collagen breakdown; this study aimed to evaluate HE4 as a biomarker for interstitial lung disease (ILD) in patients with idiopathic inflammatory myopathies (IIMs).
- Researchers enrolled 90 IIMs patients and 42 healthy controls, finding that serum HE4 levels were significantly higher in patients with IIMs, particularly in those diagnosed with ILD.
- The study concluded that HE4 levels could serve as a useful biomarker for detecting and assessing ILD in IIMs patients, although there was no significant link between baseline HE4 and progressive fibrosing ILD in follow-up cases.
The approval of biologics, namely belimumab and anifrolumab, is being a game-changer in the approach to systemic lupus erythematosus (SLE). Currently we are indeed facing a revolution in the treatment paradigm of SLE, encompassing early combination of biologics with standard treatment in severe manifestations. In this regard, a lively discussion is taking place regarding the better positioning of biologics in the treatment of not necessarily severe, yet refractory and/or disfiguring manifestations which expose patients to worsened quality of life, reduced workability and enhanced risk of organ damage especially related to the misuse of glucocorticoids in the long run.
View Article and Find Full Text PDFObjective: Our aim was to assess efficacy and safety of Rituximab (RTX) in patients with refractory Idiopathic inflammatory myopathies (IIM) from a monocentric cohort. Thereafter, we evaluated the efficacy of a low-dose RTX regimen as a remission-maintenance therapy.
Methods: We retrospectively evaluated a cohort of patients affected with IIM treated with RTX.
Introduction: Tau-positron emission tomography (PET) outcome data of patients with Alzheimer's disease (AD) cannot currently be meaningfully compared or combined when different tracers are used due to differences in tracer properties, instrumentation, and methods of analysis.
Methods: Using head-to-head data from five cohorts with tau PET radiotracers designed to target tau deposition in AD, we tested a joint propagation model (JPM) to harmonize quantification (units termed "CenTauR" [CTR]). JPM is a statistical model that simultaneously models the relationships between head-to-head and anchor point data.